Navigation Links
Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Date:3/2/2009

ways, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding the expected safety profile of Marqibo, the expected benefit Marqibo may have for patients with relapsed ALL, the timing, progress and anticipated results of the clinical development, regulatory processes, any benefits that Hana will actually realize from orphan medicinal drug or fast-track designation, and rates of patient enrollment of the rALLy trial of Marqibo. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there is no assurance that Hana will have sufficient capital to complete the development of Marqibo, that the safety profile of Marqibo observed to date will be predictive of future results, that the results of the rALLy trial to date will be predictive of future results, that the rALLy trial will meet its study objectives, that Hana's development efforts relating to Marqibo will be successful, that Hana will be able to obtain regulatory approval of Marqibo, and that the results of clinical trials will support Hana's claims or beliefs concerning the effectiveness of Marqibo in relapsed ALL or other diseases. Additional risks that may affect such forward- looking statements include Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended
'/>"/>
SOURCE Hana Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
(Date:12/19/2014)... (HealthDay News) -- Injectable drug users who also use ... rate of other substance users, a new study finds. ... the risk of suicide attempt and completed suicide," Didier ... said in a university news release. "However, there are ... know who among substance users were actually more likely ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The cost of cancer ... a new study finds. Researchers examined data from ... diagnosed with colorectal or lung cancer. Of those patients, ... and more than 100 had advanced cancer. Nearly ... pay their medical bills, which was linked with a ...
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... the United States -- along with Angelina Jolie,s chickenpox ... highlighted cracks in the nation,s public health defense against ... released Thursday. Half of U.S. states are poorly ... outbreaks. That was the main conclusion of the report ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Hospital in Franklin, Ind. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... service hospital providing care to the residents of Johnson ...
Breaking Medicine News(10 mins):Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... Phase II Clinical Trial conducted by a cancer institute in ... kidney cancer with the help of bevacizumab and erlotinib[1], the ... and may help in prolonging patient's survival. ,Renal ... especially once it has started to spread to other sites ...
... vision through cell transplants when they treated animals suffering from ... eye damages similar to that seen in many human eye ... which had lost their sight, leading to hopes that it ... happened when immature retinal stem cells were transplanted into the ...
... The AMA Federal Council has rejected outright Pharmaceutical ... are currently being pushed by some medical groups. ... today that any PBS savings derived from changed ... PBS. ,'Evidence-based prescribing information and other ...
... (ADRA) is making preparations for the annual commemoration of World ... is meant to be observed as the international day of ... ,The theme of ADRA's for 2006 is, "AIDS ... and it encourages people all over the world to realize ...
... of developing pancreatic cancer increases by 90% with the intake of ... 70% higher in people who added sugar to any food or ... who added no sugar. ,In spite of high sugar ... the first time that researchers have shown a direct association between ...
... breast cancer charity went bankrupt after it was apparent ... the cause. // Tony Freeman, 40, the man who ... at the High Court in Glasgow for 18 months ... Consultancy (Solutions RMC), raised money for several cancer charities, ...
Cached Medicine News:Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Cell Transplants Can Even Help In Restoring Vision 2Health News:Commemoration of World AIDS Day 2Health News:Charity swindler jailed over cash fraud 2
... analyzer is an affordable system offering ... reliability and consistency of state-of-the-art instrument-based ... way to obtain dependable urine chemistry ... economy of motion and superior efficiency ...
... device consists of a non-compliant balloon with ... longitudinally on its outer surface. When the ... atherotomes score the plaque, creating initiation sites ... as Atherotomy, allows dilatation of the target ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
Medicine Products: